Login to Your Account



Compound Agnostic?

Array's $713M ChK-1 Deal with Genentech Pays Either Way

By Trista Morrison


Wednesday, August 10, 2011
Roche AG's Genentech subsidiary agreed to pay Array BioPharma Inc. $28 million up front and as much as $685 million in milestones, plus double-digit royalties, for rights to the preclinical ChK-1 inhibitor ARRY-575.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription